Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen . Clinics [Internet]. 2009 May 1 [cited 2024 Jun. 15];64(5):415-20. Available from: https://www.revistas.usp.br/clinics/article/view/18033